Harmony Biosciences (NASDAQ: HRMY) — Perfil da empresa, notícias e dados financeiros
Harmony Biosciences develops treatments for neurological disorders, focusing on improving quality of life for patients with sleep issues.
Harmony Biosciences
Harmony Biosciences (NASDAQ:HRMY) focuses on developing and delivering innovative treatments for neurological disorders, particularly those that affect sleep and wakefulness. With a commitment to addressing unmet medical needs, Harmony's efforts are centered on bringing forward therapies that can significantly improve patients' quality of life. A key project for the company has been the successful development and commercialization of a treatment for narcolepsy, demonstrating their dedication to enhancing healthcare outcomes for individuals dealing with challenging conditions. Harmony Biosciences aims to expand its portfolio through strategic collaborations, ongoing research, and the exploration of novel therapeutics to further its objective of transforming lives through science.
Resumo
Operações
Produtos e/ou serviços de Harmony Biosciences
- WAKIX (pitolisant) - A medication for treating narcolepsy, addressing symptoms like excessive daytime sleepiness and cataplexy.
- Research in Narcolepsy - Focused on advancing treatments for sleep disorders, particularly narcolepsy.
- Development in Prader-Willi Syndrome - Engaged in creating therapies for managing this genetic condition, emphasizing hyperphagia control.
- R&D in Excessive Daytime Sleepiness - Dedicated projects exploring new solutions for excessive daytime sleepiness across various conditions.
- Pipeline Expansion - Actively exploring opportunities to augment their portfolio with novel therapeutics in central nervous system disorders.
- Collaborations for Rare Diseases - Partnering with other entities to accelerate the development of treatments for rare neurological conditions.
equipe executiva do Harmony Biosciences
- Jeffrey S. AroninFounder & Non-Executive Chairman
- Jeffrey M. DaynoPresident, CEO & Director
- Kumar BudurExecutive VP and Chief Medical & Scientific Officer
- Andrew SerafinExecutive VP & Chief Strategy Officer
- Adam ZaeskeExecutive VP & Chief Commercial Officer
- Stephen MollichellaSenior VP, Controller & Interim Principal Financial Officer
- Brennan DoyleVP & Head of Investor Relations
- Christian UlrichExecutive VP, General Counsel & Corporate Secretary
- Tricia GloverChief Compliance Officer
- Audrey MurphyChief Human Resources Officer
Últimas notícias sobre a Harmony Biosciences
Principais indicadores financeiros
Resultados divulgados pela Harmony Biosciences, em USD.
- Cap. de mercado
- 2,2 bi
- Receita (TTM)
- 959,9 mi
- P/L
- 12.4
- LPA (diluído, TTM)
- 3.1
- Dividend yield
- —
- Margem de lucro
- 18.9%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 868,5 mi | 208,5 mi | 158,7 mi | |
| 714,7 mi | 190,8 mi | 145,5 mi | |
| 582 mi | 192 mi | 128,9 mi | |
| 437,9 mi | 120,2 mi | 181,5 mi |